Core Insights - GSK raised its 2025 sales and earnings forecasts due to strong performance in specialty HIV and cancer medicines, despite a significant drop in U.S. sales of its shingles vaccine Shingrix [1][2] - The company's shares increased by as much as 4.3%, reaching their highest level since May 2024, and have risen 25% so far in 2025 [1] Sales Performance - Overall vaccine sales for GSK reached 2.68 billion pounds in the quarter ending September 30, surpassing analyst expectations of 2.55 billion pounds [2] - Sales of the shingles vaccine Shingrix fell by 15% in the U.S., contributing to a cautious outlook for the U.S. market [3][5] Competitive Landscape - GSK's influenza vaccine sales also declined in the U.S. due to increased competition, mirroring trends seen by rival Sanofi [4] - The company faces challenges from U.S. vaccine sales pressures, including funding cuts for vaccine research and a negative public perception of vaccines [3][4] Future Outlook - GSK maintained its forecast for a low-single-digit decrease to broadly stable revenues for vaccines, which accounted for over a third of its third-quarter revenues [5] - The company aims to achieve annual revenues exceeding 40 billion pounds ($54 billion) by 2031, with expected annual revenue growth of 6% to 7% and core earnings per share growth of 10% to 12% [6] Financial Performance - GSK reported core earnings per share of 55 pence on sales of 8.55 billion pounds for the quarter, exceeding analyst expectations of 47.1 pence on sales of 8.24 billion pounds [7]